OR WAIT null SECS
Manufacturing of the vaccine will take place at Baxter’s fill/finish sterile manufacturing facilities located in Bloomington, IN.
Baxter and Moderna announced on March 8, 2021 that they have entered into an agreement where Baxter’s contract manufacturing organization, Baxter BioPharma Solutions, will provide fill/finish sterile manufacturing services and supply packaging for 60–90 million doses of the Moderna COVID-19 vaccine in 2021.
Under the terms of the agreement, manufacturing of the vaccine will take place at Baxter’s fill/finish sterile manufacturing facilities located in Bloomington, IN, Baxter said in a company press release. Additional details of the partnership were not disclosed.
“We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for COVID-19,” said Marie Keeley, vice-president, Baxter BioPharma Solutions, in the press release. “Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.”
“We welcome the opportunity to work with Baxter BioPharma Solutions on fill/finish manufacturing for the Moderna COVID-19 vaccine in the [United States],” added Juan Andres, Moderna’s chief technical operations and quality officer, in the press release. “This additional production will help us continue to scale up our manufacturing capacity in the [US].”